Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study

Complementary Therapies in Medicine

Volumn 20, Issue 3, 2012, Pages 124-130

  Bruyere O ^a   Zegels, B ^a   Leonori, L ^a   Rabenda, V ^a   Janssen, A ^a   Bourges, C ^b   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NONE

Author keywords

Collagen hydrolysate; Joint; Nutrition; Pain; Randomized controlled study

Indexed keywords

ANALGESIC AGENT; COLLAGEN HYDROLYSATE; GENACOL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; KIDNEY DISEASE; LIMB PAIN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARALLEL DESIGN; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SENSORY DYSFUNCTION; SKIN DISEASE; UROGENITAL TRACT DISEASE; VISUAL ANALOG SCALE;

AGED; ANALGESICS; ARTHRALGIA; COLLAGEN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PROTEIN HYDROLYSATES;

EID: 84859718316     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2011.12.007     Document Type: Article

References (22)

1. Birrell F.N. Patterns of joint pain: lessons from epidemiology. Rheumatology (Oxford) 2004, 43(April (4)):408-409.
2. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16(February (2)):137-162.
3. Schaffer D., Florin T., Eagle C., Marschner I., Singh G., Grobler M., et al. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust 2006, 185(November (9)):501-506.
4. Singh G., Wu O., Langhorne P., Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006, 8(5):R153.
5. Lee F.H., Raja S.N. Complementary and alternative medicine in chronic pain. Pain 2011, 152(January (1)):28-30.
6. Santaguida P.L., Gross A., Busse J., Gagnier J., Walker K., Bhandari M., et al. Complementary and alternative medicine in back pain utilization report. Evid Rep Technol Assess (Full Rep) 2009, 177(January):1-221.
7. Henrotin Y., Lambert C., Couchourel D., Ripoll C., Chiotelli E., Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products. Osteoarthritis Cartilage 2011, 19(January (1)):1-21.
8. Lequesne M.G. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol 1997, 24(April (4)):779-781.
9. Lequesne M.G., Mery C., Samson M., Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987, 65:85-89.
10. Hudak P.L., Amadio P.C., Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected] The Upper Extremity Collaborative Group (UECG). Am J Ind Med 1996, 29(June (6)):602-608.
11. Roland M., Morris R. A study of the natural history of back pain Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976) 1983, 8(March (2)):141-144.
12. Lauridsen H.H., Hartvigsen J., Manniche C., Korsholm L., Grunnet-Nilsson N. Responsiveness and minimal clinically important difference for pain and disability instruments in low back pain patients. BMC Musculoskelet Disord 2006, 7:82.
13. Beaton D.E., Katz J.N., Fossel A.H., Wright J.G., Tarasuk V., Bombardier C. Measuring the whole or the parts? Validity, reliability, and responsiveness of the disabilities of the arm, shoulder and hand outcome measure in different regions of the upper extremity. J Hand Ther 2001, 14(April-June (2)):128-146.
14. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16(December (3)):199-208. The EuroQol Group.
15. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(June (6)):473-483.
16. Clark K.L., Sebastianelli W., Flechsenhar K.R., Aukermann D.F., Meza F., Millard R.L., et al. 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain. Curr Med Res Opin 2008, 24(May (5)):1485-1496.
17. Moskowitz R.W. Role of collagen hydrolysate in bone and joint disease. Semin Arthritis Rheum 2000, 30(October (2)):87-99.
18. Horvath G., Koroknai G., Acs B., Than P., Bellyei A., Illes T. Prevalence of radiographic primary hip and knee osteoarthritis in a representative Central European population. Int Orthop 2010, June.
19. Elder S.H., Borazjani A. Effect of collagen hydrolysate on chondrocyte-seeded agarose constructs. Biomed Mater Eng 2009, 19(6):409-414.
20. Ng K.W., Saliman J.D., Lin E.Y., Statman L.Y., Kugler L.E., Lo S.B., et al. Culture duration modulates collagen hydrolysate-induced tissue remodeling in chondrocyte-seeded agarose hydrogels. Ann Biomed Eng 2007, 35(November (11)):1914-1923.
21. Bello A.E., Oesser S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Curr Med Res Opin 2006, 22(November (11)):2221-2232.
22. Oesser S., Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res 2003, 311(March (3)):393-399.